Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy - PubMed (original) (raw)
Clinical Trial
. 1994 Jan 3;167(1-2):145-60.
doi: 10.1016/0022-1759(94)90084-1.
Affiliations
- PMID: 8308273
- DOI: 10.1016/0022-1759(94)90084-1
Clinical Trial
Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy
R S Freedman et al. J Immunol Methods. 1994.
Abstract
Tumor infiltrating lymphocytes (TIL) from malignant ascites or solid tumor specimens obtained from patients with ovarian carcinoma were expanded to large numbers in vitro (10(10)-10(11)) by a four-step method using AIM V medium and low concentrations of recombinant interleukin-2 (rIL-2). The expansion procedure employed 24-well culture plates, T-flasks, polyolefin gas-permeable bags (PGPB), and an artificial capillary culture system (ACCS). The mean number of mononuclear leukocytes introduced into the 24-well plates was 16.5 +/- 4.2 x 10(6) cells. TIL from a total of 16 patients were expanded only through the first three steps of the process (24-well-plates, T-flasks, and PGPB) with an overall expansion of 255 +/- 99 fold and mean duration of 27.4 +/- 2.2 days. TIL from 9 of 16 patients were expanded further through the fourth step (ACCS) of the expansion method. The cumulative fold-expansion in nine patients was 8044 +/- 4807 (mean +/- SEM), the median was 2876 and the mean expansion time was 47.1 +/- 4.7 days. TIL from seven additional patients did not grow in rIL-2. Six of these 7 patients received chemotherapy at least four weeks before the specimens were collected. Two ACCS were used in parallel to facilitate expansion of TIL. Viable rIL-2-expanded TIL in the range of 1 x 10(10)-1 x 10(11) were recovered from the two ACCS, a number sufficient for adoptive immunotherapy of patients with ovarian carcinoma. The rIL-2-expanded TIL were predominantly CD3+ CD4+ CD8- alpha beta TCR+, although CD3+ CD4- CD8+ alpha beta TCR+ T cell lines were obtained from certain patients. An increase (43 +/- 8 vs 75 +/- 13; P = 0.05) in the proportion of CD4+ cells was observed over the duration of the four expansion steps. However, CD8+ TIL-derived T cells lines were also expanded in the ACCS. The four-step expansion method described here has several significant advantages over existing techniques. It requires substantially less personnel, equipment and space and the risk of contamination during expansion of the cultures is decreased. These results demonstrate that the four-step method described here can be effectively used for the large-scale expansion of ovarian TIL for the treatment of patients with ovarian carcinoma by adoptive immunotherapy.
Similar articles
- Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S, et al. Freedman RS, et al. J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210. doi: 10.1097/00002371-199410000-00004. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7834119 Clinical Trial. - Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Baxevanis CN, et al. Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. Cancer. 1994. PMID: 7914469 - Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD. Freedman RS, et al. Clin Cancer Res. 2000 Jun;6(6):2268-78. Clin Cancer Res. 2000. PMID: 10873077 Clinical Trial. - Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
Freedman RS, Platsoucas CD. Freedman RS, et al. Cancer Treat Res. 1996;82:115-46. doi: 10.1007/978-1-4613-1247-5_8. Cancer Treat Res. 1996. PMID: 8849947 Review. - Novel immunologic strategies in ovarian carcinoma.
Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD. Freedman RS, et al. Am J Obstet Gynecol. 1992 Nov;167(5):1470-8. doi: 10.1016/s0002-9378(11)91735-9. Am J Obstet Gynecol. 1992. PMID: 1332480 Review.
Cited by
- Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.
Garcia-Aponte OF, Herwig C, Kozma B. Garcia-Aponte OF, et al. J Biol Eng. 2021 Apr 13;15(1):13. doi: 10.1186/s13036-021-00264-7. J Biol Eng. 2021. PMID: 33849630 Free PMC article. Review. - CD137+ T-Cells: Protagonists of the Immunotherapy Revolution.
Ugolini A, Nuti M. Ugolini A, et al. Cancers (Basel). 2021 Jan 26;13(3):456. doi: 10.3390/cancers13030456. Cancers (Basel). 2021. PMID: 33530328 Free PMC article. Review. - Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.
Zhang W, Liu K, Ye B, Hu G, Zhao K, Ren Y, Liang W. Zhang W, et al. Oncol Lett. 2017 Sep;14(3):3379-3386. doi: 10.3892/ol.2017.6635. Epub 2017 Jul 20. Oncol Lett. 2017. PMID: 28927091 Free PMC article. - Monocyte and interferon based therapy for the treatment of ovarian cancer.
Green DS, Nunes AT, Annunziata CM, Zoon KC. Green DS, et al. Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15. Cytokine Growth Factor Rev. 2016. PMID: 27026228 Free PMC article. - Tumor infiltrating lymphocytes in ovarian cancer.
Santoiemma PP, Powell DJ Jr. Santoiemma PP, et al. Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960. Epub 2015 Apr 20. Cancer Biol Ther. 2015. PMID: 25894333 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials